These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15917650)

  • 1. Inhibition of c-fms by imatinib: expanding the spectrum of treatment.
    Dewar AL; Zannettino AC; Hughes TP; Lyons AB
    Cell Cycle; 2005 Jul; 4(7):851-3. PubMed ID: 15917650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
    Dewar AL; Cambareri AC; Zannettino AC; Miller BL; Doherty KV; Hughes TP; Lyons AB
    Blood; 2005 Apr; 105(8):3127-32. PubMed ID: 15637141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis.
    Paniagua RT; Sharpe O; Ho PP; Chan SM; Chang A; Higgins JP; Tomooka BH; Thomas FM; Song JJ; Goodman SB; Lee DM; Genovese MC; Utz PJ; Steinman L; Robinson WH
    J Clin Invest; 2006 Oct; 116(10):2633-42. PubMed ID: 16981009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.
    Hiraga T; Nakamura H
    Int J Cancer; 2009 Jan; 124(1):215-22. PubMed ID: 18814279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
    Toga W; Kondo M; Tokoro A
    Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of chronic myeloid leukemia with imatinib mesylate.
    Ohno R
    Int J Clin Oncol; 2006 Jun; 11(3):176-83. PubMed ID: 16850123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
    Knight GW; McLellan D
    Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
    Nadal E; Olavarria E
    Int J Clin Pract; 2004 May; 58(5):511-6. PubMed ID: 15206509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of imatinib (STI571).
    Buchdunger E; O'Reilly T; Wood J
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
    Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
    Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
    Nardi V; Azam M; Daley GQ
    Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
    Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
    Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
    Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
    Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
    Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
    Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
    Taylor JR; Brownlow N; Domin J; Dibb NJ
    Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
    Giles FJ; Cortes JE; Kantarjian HM
    Curr Mol Med; 2005 Nov; 5(7):615-23. PubMed ID: 16305488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelogenous leukaemia--new therapeutic principles.
    O'Dwyer ME; Druker BJ
    J Intern Med; 2001 Jul; 250(1):3-9. PubMed ID: 11454136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.